Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission

Blood

Volumn 89, Issue 9, 1997, Pages 3330-3334

  El Rifai, Wa'el ^b   Ruutu, Tapani ^b   Elonen, Erkki ^b   Volin, Liisa ^b   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METAPHASE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS;

EID: 0030917739     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.9.3330     Document Type: Article

References (30)

1. Rowe JM, Liesveld JL: Treatment and prognostic factors in acute myeloid leukemia. Bailliere Clin Haematol 9:87, 1996
2. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. [European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups]. N Engl J Med 332:217, 1995
3. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R, Dicke KA, Klein JP, Lowenberg B, Reiffers J, Rimm AA, Rowlings PA, Sandberg AA, Sobocinski KA, Veum-Stone J, Bortin MM: Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 16:203, 1995
4. Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, Kim KM, Zhang MJ, Ash RC, Atkinson K, Champlin RE, Dicke KA, Gajewski JL, Goldman JM, Helbig W, Henslee Downey PS, Hinterberger W, Jacobsen N, Keating A, Klein JP, Marmont AM, Prentice HG, Reiffers J, Rimm AA, Bortin MM: Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10:13, 1996
5. Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM: Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 6:500, 1992
6. Dastugue N, Payen C, Lafage Pochitaloff M, Bernard P, Leroux D, Huguet Rigal F, Stoppa AM, Marit G, Molina L, Michallet M, Maraninchi D, Altal M, Reiffers J: Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 9:1491, 1995
7. Campana D, Pui C-H: Detection of minimal residual disease in acute leukemia: Methodologie advances and clinical significance. Blood 85:1416, 1995
8. Kwong YL, Wong KF, Chang V, Chan CH: Persistence of AML 1 rearrangement in peripheral blood cells in t(8;21). Cancer Genet Cytogenet 88:151, 1996
9. Kwong YL, Chan V, Wong KF, Chan TK: Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer 75:821, 1995
10. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger L, Mitterbauer G, Purtscher B, Haas OA, Lechner K, Jaeger U: AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735, 1994
11. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Drabkin HA, Willman C, Theil KS, Civin CL, Erickson P: An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8; 21 )(q22; q22) translocation. Blood 81:2860, 1993
12. Chang KS, Fan YH, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H: Expression of AMLI-ETO fusion transcripts and detection of minimal residual disease in t(8; 21)-positive acute myeloid leukemia. Oncogene 8:983, 1993
13. Maruyama F, Stass SA, Estey EH, Cork A, Hirano M, Ino T, Freireich EJ, Yang P, Chang KS: Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8:21) positive acute myelogenous leukemia. Leukemia 8:40, 1994
14. Nucifora G, Larson RA, Rowley JD: Persistence of the 8; 21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood 82:712, 1993
15. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AMW, Knuutila S, Herzig GP, Bloomfield CD: Persistence of the AMLI/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 88:2183, 1996
16. El-Rifai W, Ruutu T, Vettenranta K, Temtamy S, Knuutila S: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: A rrietaphase-FISH study. Br J Haematol 92:365, 1996
17. Nylund SJ, Ruutu T, Saarinen U, Larramendy ML, Knuutila S: Detection of minimal residual disease using fluorescence DNA in situ hybridization: A follow-up study in leukemia and lymphoma patients. Leukemia 8:587, 1994
18. Nylund SJ, Ruutu T, Saarinen U, Knuutila S: Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. Br J Haematol 88:778, 1994
19. Zhao L, Kantarijan HM, Van Oort J, Cork A, Trujillo JM, Liang JC: Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML in complete remission after interferon treatment. Leukemia 7:168, 1993
20. El-Rifai W, Ruutu T, Vettenranta K, Elonen E, Saarinen UM, Volin L, Knuutila S: Follow-up of residual disease using metaphase-FISH in patients with acute lymphoblastic leukemia in remission. Leukemia (in press)
21. ISCN: Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature (ed. by F. Mitelman). Basel, Switzerland, Karger, 1995
22. Cremer T, Lichter P, Borden J, Ward DC, Manuelidis L: Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes. Human Genet 80:235, 1988
23. Pinkel D, Straume T, Gray JW: Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 83:2934, 1986
24. Hook EB: Exclusion of chromosomal mosaicism: Tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 29:94, 1977
25. Marmont AM: The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML). Leuk Lymphoma 11:221, 1993 (suppl 1)
26. Feig SA, Lampkin B, Nesbit ME, Woods WG, Versteeg CM, Buckley JD, Kim T, Hammond GD: Outcome of BMT during first complete remission of AML: A comparison of two sequential studies by the Children's Cancer Group. Bone Marrow Transplant 12:65, 1993
27. Giralt S, Champlin R: Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 84:3603, 1994
28. Chang KS, Trujillo JM, Ogura T, Castiglione CM, Kidd KK, Zhao SR, Freireich EJ, Stass SA: Rearrangement of the retinoic acid receptor gene in acute promyelocytic leukemia. Leukemia 5:200, 1991
29. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10, 1994
30. LoCoco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Melone G, Mandelli F, Grignani F, Masera G, Barbui T, Pelicci PG: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 340:1437, 1992